Subscribe To
IMVT / Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus
IMVT News
By The Motley Fool
September 27, 2023
Why Immunovant Stock Is Bolting Higher Today
Tuesday, Immunovant announced early-stage trial results for an autoimmune disease candidate that caused its shares to rocket higher. Investors are bid more_horizontal
By Seeking Alpha
September 27, 2023
Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock
Although Immunovant's stock has rallied around 100% since January, recent data on its therapeutic candidate, IMVT-1402, has further bolstered confiden more_horizontal
By Investopedia
September 26, 2023
Immunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats Expectations
Immunovant (IMVT) shares virtually doubled on Tuesday after the biopharmaceutical company reported positive results from a Phase 1 trial of its experi more_horizontal
By The Motley Fool
September 26, 2023
Why Shares of Immunovant Are Soaring on Tuesday
Immunovant reported positive phase 1 trial data for IMVT-1402. The company said the therapy showed a strong safety profile and fewer side effects than more_horizontal
By Proactive Investors
September 26, 2023
Immunovant and Roivant jump as new drug shapes up to become blockbuster
There was a bumper boost for stock in two Nasdaq-listed biotechs premarket after an experimental antibody treatment was revealed to have blockbuster p more_horizontal
By The Motley Fool
September 26, 2023
These 2 Biotech Stocks Are Bucking a Down Market Tuesday
Markets moved lower on Tuesday, giving up some gains from Monday. Immunovant released positive trial data that sent its shares soaring. more_horizontal
By GlobeNewsWire
September 25, 2023
Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023
NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives f more_horizontal
By Zacks Investment Research
August 11, 2023
Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus
Immunovant's (IMVT) reports wider-than-expected loss for fiscal first-quarter 2023. IMVT is on track with the pipeline developments. more_horizontal